Evidence map›Paper›PMID 23345639›Full record

Trial reportNeurology2013

A randomized trial of pregabalin in patients with neuropathic pain due to spinal cord injury.

Diana D Cardenas, Edward C Nieshoff, Kota Suda, Shin-Ichi Goto, Luis Sanin, Takehiko Kaneko, Jonathan Sporn, Bruce Parsons, Matt Soulsby, Ruoyong Yang and 4 more

Open access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Neurology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 13 pooled it
12.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 13 syntheses or guidelines pooled it, 185 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Pooled it
  8. Pregabalin for neuropathic pain in adults.The Cochrane database of systematic reviews · 2019
    Pooled it
  9. Pooled it
  10. Guideline
  11. Guideline
  12. Pooled it
  13. Guideline
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. Article
  20. Review

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Diana D CardenasDepartment of Rehabilitation Medicine, The Leonard M. Miller School of Medicine, University of Miami, FL, USA. dcardenas@med.miami.edu
Edward C Nieshoff
Kota Suda
Shin-Ichi Goto
Luis Sanin
Takehiko Kaneko
Jonathan Sporn
Bruce Parsons
Matt Soulsby
Ruoyong Yang
Ed Whalen
Joseph M Scavone
Makoto M Suzuki
Lloyd E Knapp
Pfizer (Japan) · JPScientific Solutions (United States) · USPfizer (United States) · USShibuya (Japan) · JPWayne State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess the efficacy and tolerability of pregabalin for the treatment of central neuropathic pain after spinal cord injury (SCI).

methodsPatients with chronic, below-level, neuropathic pain due to SCI were randomized to receive 150 to 600 mg/d pregabalin (n = 108) or matching placebo (n = 112) for 17 weeks. Pain was classified in relation to the neurologic level of injury, defined as the most caudal spinal cord segment with normal sensory and motor function, as above, at, or below level. The primary outcome measure was duration-adjusted average change in pain. Key secondary outcome measures included the change in mean pain score from baseline to end point, the percentage of patients with ≥30% reduction in mean pain score at end point, patient global impression of change scores at end point, and the change in mean pain-related sleep interference score from baseline to end point. Additional outcome measures included the medical outcomes study-sleep scale and the Hospital anxiety and depression scale.

resultsPregabalin treatment resulted in statistically significant improvements over placebo for all primary and key secondary outcome measures. Significant pain improvement was evident as early as week 1 and was sustained throughout the treatment period. Adverse events were consistent with the known safety profile of pregabalin and were mostly mild to moderate in severity. Somnolence and dizziness were most frequently reported.

conclusionsThis study demonstrates that pregabalin is effective and well tolerated in patients with neuropathic pain due to SCI. CLASSIFICATION OF EVIDENCE: This study provides class I evidence that pregabalin, 150 to 600 mg/d, is effective in reducing duration-adjusted average change in pain compared with baseline in patients with SCI over a 16-week period (p = 0.003, 95% confidence interval = -0.98, -0.20).

Indexed as

AnalgesicsDouble-Blind MethodFemalegamma-Aminobutyric AcidHumansMaleMiddle AgedNeuralgiaPregabalinSleepSpinal Cord InjuriesTreatment OutcomeAnalgesicsgamma-Aminobutyric AcidPregabalin

Identifiers

PMID23345639
PMCPMC3589291
OpenAlexW2038826804

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.